BCL, too.

You know that constitutive activation of the antiapoptotic BCL2 protein is a notorious offender in the development of heme malignancies. What you may not know is it upgraded its status to targetable with the market entry of venetoclax. The phase 3 MURANO trial reported last week demonstrates, among almost 400 patients with relapsed/refractory chronic lymphocytic leukemia, the combo of venetoclax and rituximab (anti-CD20) more than doubles the rate of progression-free survival at 2 years (36 -> 85%) when compared to the standard bendamustine and rituximab. | Seymour, N Engl J Med 2018